ETEyasu H. Teshale

Eyasu H. Teshale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eyasu H. Teshale has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Updated Hepatitis D Seroprevalence Among Hepatitis B Surface Antigen-Positive Persons Aged ≥6 Years in the United States, National Health and Nutrition Examination Survey, 2007‒2018

    by Shannon M Casillas, Asiya Chida, Jan Drobeniuc, Amy L Sandul, Saleem Kamili, Ruth B Jiles, David L Thomas, Aaron A R Tobian, Eshan U Patel, Eyasu H Teshale

    To validate the accuracy of previously published US seroprevalence estimates for hepatitis D virus (HDV) antibody, we retested National Health and Nutrition Examination Survey samples from 2007 to 2018 using a different assay. We found the HDV seroprevalence among hepatitis B surface antigen-positive participants aged ≥6 years to be 1.26%.

  • Disparities in hepatitis C among people aged 12–59 with no history of injection drug use, United States, January 2013–March 2020

    by Kathleen N. Ly, Laurie K. Barker, Greta Kilmer, Jaimie Z. Shing, Ruth B. Jiles, Eyasu Teshale

    Background and Aims: In the United States, hepatitis C virus (HCV) infection occurs primarily through injection drug use (IDU), but transmission also occurs through other ways. This study examined HCV prevalence and disparities among US residents aged 12–59 years with no IDU history.Methods: We analysed 2013‐March 2020 National Health and Nutrition Examination Survey data to calculate the HCV prevalence among people with no drug use history and only a non‐IDU history, collectively referred to as no IDU history. These estimates were compared to those with an IDU history and stratified by sociodemographic and hepatitis A and hepatitis B serologic characteristics.Results: The current HCV infection prevalence among people aged 12–59 was .7% overall, and specifically 17.2% among people with an IDU history, .9% among people with a non‐IDU history and .2% among people with no drug use history. These rates represented 1.4 million people with current HCV infection, of whom, 730 000 had an IDU history, 262 000 had a non‐IDU history and 309 000 had no drug use history. Among people with no drug use history, current HCV infection prevalence was higher for people born during 1954–1965 versus after 1965, had completed high school or less versus at least some college and had past/present hepatitis B versus vaccinated for hepatitis B.Conclusion: While the HCV infection burden was highest among people with an IDU history, we found a sizeable burden among people without such a history. These findings support policies and practices aimed at addressing disparities among people needing treatment.


  • Prevalence and awareness of Hepatitis B virus infection in the United States: January 2017 - March 2020

    by Danae Bixler, Laurie Barker, Karon Lewis, Lauren Peretz, Eyasu Teshale

    Background: Prevalence and awareness of HBV infection are important national indicators of progress toward hepatitis B elimination. Methods: National Health and Nutrition Examination Survey participants were examined for laboratory evidence of HBV infection (positive antibody to HBcAg and HBsAg), and interviewed to determine awareness of HBV infection. Estimates of HBV infection prevalence and awareness were calculated for the US population. Findings: Among National Health and Nutrition Examination Survey participants aged 6 years and older evaluated from January 2017 through March 2020, an estimated 0.2% had HBV infection; of these 50% were aware of their infection.


  • Open Access

    Characteristics of Persons Treated for Hepatitis C Using National Pharmacy Claims Data, United States, 2014–2020

    by Eyasu H Teshale, Henry Roberts, Neil Gupta, Ruth Jiles

    Using national pharmacy claims data for 2014–2020, 843 329 persons were treated for hepatitis C at least once. The proportion treated increased annually among persons aged <40 years, insured by Medicaid, and treated by primary care providers. Monitoring hepatitis C treatment is essential to identify barriers to treatment access.


  • Open Access

    Trends in Indicators of Injection Drug Use, Indian Health Service, 2010-2014

    by Mary E. Evans, Marissa Person, Brigg Reilley, Jessica Leston, Richard Haverkate, Jeffrey T. McCollum, Andria Apostolou, Michele K. Bohm, Michelle Van Handel, Danae Bixler, et al.

    Objectives: Hepatitis C virus (HCV) and HIV transmission in the United States may increase as a result of increasing rates of opioid use disorder (OUD) and associated injection drug use (IDU). Epidemiologic trends among American Indian/Alaska Native (AI/AN) persons are not well known. Methods: We analyzed 2010-2014 Indian Health Service data on health care encounters to assess regional and temporal trends in IDU indicators among adults aged ≥18 years. IDU indicators included acute or chronic HCV infection (only among adults aged 18-35 years), arm cellulitis and abscess, OUD, and opioid-related overdose. We calculated rates per 10 000 AI/AN adults for each IDU indicator overall and stratified by sex, age group, and region and evaluated rate ratios and trends by using Poisson regression analysis. Results: Rates of HCV infection among adults aged 18-35 increased 9.4% per year, and rates of OUD among all adults increased 13.3% per year from 2010 to 2014. The rate of HCV infection among young women was approximately 1.3 times that among young men. Rates of opioid-related overdose among adults aged <50 years were approximately 1.4 times the rates among adults aged ≥50 years. Among young adults with HCV infection, 25.6% had concurrent OUD. Among all adults with arm cellulitis and abscess, 5.6% had concurrent OUD. Conclusions: Rates of HCV infection and OUD increased significantly in the AI/AN population. Strengthened public health efforts could ensure that AI/AN communities can address increasing needs for culturally appropriate interventions, including comprehensive syringe services programs, medication-assisted treatment, and opioid-related overdose prevention and can meet the growing need for treatment of HCV infection.


  • Open Access

    Estimated cost of comprehensive syringe service program in the United States

    by Eyasu H. Teshale, Alice Asher, Maria V. Aslam, Ryan Augustine, Eliana Duncan, Alyson Rose-Wood, John Ward, Jonathan Mermin, Kwame Owusu-Edusei, Patricia M. Dietz

    To estimate the cost of establishing and operating a comprehensive syringe service program (SSP) free to clients in the United States. We identified the major cost components of a comprehensive SSP: (one-time start-up cost, and annual costs associated with personnel, operations, and prevention/medical services) and estimated the anticipated total costs (2016 US dollars) based on program size (number of clients served each year) and geographic location of the service (rural, suburban, and urban). The estimated costs ranged from $0.4 million for a small rural SSP (serving 250 clients) to $1.9 million for a large urban SSP (serving 2,500 clients), of which 1.6% and 0.8% is the start-up cost of a small rural and large urban SSP, respectively. Cost per syringe distributed varied from $3 (small urban SSP) to $1 (large rural SSP), and cost per client per year varied from $2000 (small urban SSP) to $700 (large rural SSP). Estimates of the cost of SSPs in the United States vary by number of clients served and geographic location of service. Accurate costing can be useful for planning programs, developing policy, allocating funds for establishing and supporting SSPs, and providing data for economic evaluation of SSPs.


  • The Prevalence of Hepatitis C Virus Antibody in HIV-Negative Persons in Kenya, 2007

    by Kathleen N. Ly, Andrea A. Kim, Jan Drobeniuc, Maja Kodani, Joel M. Montgomery, Barry S. Fields, Eyasu H. Teshale

    The prevalence of hepatitis C virus (HCV) infection in the Kenyan population has not been previously determined. We estimated the Kenyan HCV prevalence in HIV-negative persons aged 15-64 years. This is a retrospective cross-sectional study using data from the 2007 Kenya AIDS Indicator Survey-a nationally representative sample of 15,853 persons aged 15-64 years who completed a health interview and provided a blood specimen. Of the 1,091 randomly selected participants, 50 tested positive for HCV antibody using the automated chemiluminescence immunoassay, corresponding to a weighted HCV antibody positivity rate of 4.4% (95% confidence interval: 3.3-5.9%) or 848,000 (range: 634,000-1,100,000) persons. Hepatitis C virus RNA, a marker for current infection, was not detected in any of the tested antibody-positive specimens. The high HCV antibody prevalence together with no current infection suggests that some HCV antibody serologic testing in Kenya may result in false positives whereas others may be because of spontaneous viral clearance.


  • Changing trends in complications of chronic hepatitis C

    by Mei Lu, Jia Li, Loralee B. Rupp, Yueren Zhou, Scott D. Holmberg, Anne C. Moorman, Philip R. Spradling, Eyasu H. Teshale, Joseph A. Boscarino, Yihe G. Daida, et al.

    Background & Aims: Chronic hepatitis C virus (HCV)‐related complications have increased over the past decade.Methods: We used join‐point regression modelling to investigate trends in these complications from 2006 to 2015, and the impact of demographics on these trends. Using data from the Chronic Hepatitis Cohort Study (CHeCS), we identified points at which the trend significantly changed, and estimated the annual percent change (APC) in rates of cirrhosis, decompensated cirrhosis and all‐cause mortality, adjusted by race, sex and age.Results: Among 11,167 adults with chronic HCV infection, prevalence of cirrhosis increased from 20.8% to 27.6% from 2006 to 2015, with adjusted annual percentage change (aAPC) of 1.2 (p <. 01). Although incidence of all‐cause mortality increased from 1.8% in 2006 to 2.9% in 2015, a join‐point was identified at 2010, with aAPCs of 9.6 before (2006 < 2010; p < .01) and −5.2 after (2010 ≤ 2015; p < .01), indicating a decrease in mortality from 2010 and onward. Likewise, overall prevalence of decompensated cirrhosis increased from 9.3% in 2006 to 10.4% in 2015, but this increase was confined to patients 60 or older (aAPC = 1.5; p = .023). Asian American and Black/African American patients demonstrated significantly higher rates of cirrhosis than White patients, while older patients and men demonstrated higher rates of cirrhosis and mortality.Conclusions: Although cirrhosis and mortality among HCV‐infected patients in the US have increased over the past decade, all‐cause mortality has decreased in recent years.


  • Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS)

    by Anne C. Moorman, Xin Tong, Philip R. Spradling, Loralee B. Rupp, Stuart C. Gordon, Mei Lu, Eyasu H. Teshale, Joseph A. Boscarino, Connie M. Trinacty, Mark A. Schmidt, et al.

    Background Guidelines for the treatment of HCV-infected persons were updated in August 2015 with new recommendations for patients with renal impairment. Treatment is imperative for patients with severe, renal-associated extrahepatic manifestations of HCV infection. Aims We sought to describe the prevalence of these conditions among current HCV-infected patients in a population-based prospective, observational cohort study at four large US health systems. Methods Data from cohort patients with chronic HCV infection during 2012 were analyzed for the period from 2006 to 2013. We determined the prevalence of mild to moderately impaired renal function defined as having the most recent estimated glomerular filtration rate [eGFR] ≤ 80 ml/min/1.73 m2, with severe impairment defined as eGFR < 30 ml/min/1.73 m2, based on the treatment guidelines. Prevalence of extrahepatic conditions was ascertained using ICD9-codes. Results Among 5772 persons, the prevalence of eGFR ≤ 80 was 33 % and eGFR < 30 was 2 %, including among patients with hepatic fibrosis. Diagnosed extrahepatic renal manifestations were rare: vasculitis- 0.2 %, nephrotic syndrome- 0.3 %, and cryoglobulinemia- 0.9 %. Conclusions While the prevalence of severe renal impairment and diagnosed extrahepatic manifestations was low, mild-to-moderate renal impairment was common in HCV patients, including those with advanced liver fibrosis for whom the need for treatment is urgent.


  • Higher all‐cause hospitalization among patients with chronic hepatitis C: the Chronic Hepatitis Cohort Study (CHeCS), 2006–2013

    by E. H. Teshale, J. Xing, A. Moorman, S. D. Holmberg, P. R. Spradling, S. C. Gordon, L. B. Rupp, M. Lu, J. A. Boscarino, C.M. Trinacity, et al.

    Summary: In the United States, hospitalization among patients with chronic hepatitis C virus (HCV) infection is high. The healthcare burden associated with hospitalization is not clearly known. We analysed data from the Chronic Hepatitis Cohort Study, an observational cohort of patients receiving care at four integrated healthcare systems, collected from 2006 to 2013 to determine all‐cause hospitalization rates of patients with chronic HCV infection and the other health system patients. To compare the hospitalization rates, we selected two health system patients for each chronic HCV patient using their propensity score (PS). Propensity score matching was conducted by site, gender, race, age and household income to minimize differences attributable to these characteristics. We also compared primary reason for hospitalization between chronic HCV patients and the other health system patients. Overall, 10 131 patients with chronic HCV infection and 20 262 health system patients were selected from the 1 867 802 health system patients and were matched by PS. All‐cause hospitalization rates were 27.4 (27.0–27.8) and 7.4 (7.2–7.5) per 100 persons‐year (PY) for chronic HCV patients and for the other health system patients, respectively. Compared to health system patients, hospitalization rates were significantly higher by site, gender, age group, race and household income among chronic HCV patients (P < 0.001). Compared to health system patients, chronic HCV patients were more likely to be hospitalized from liver‐related conditions (RR = 24.8, P < 0.001). Hence, patients with chronic HCV infection had approximately 3.7‐fold higher all‐cause hospitalization rate than other health system patients. These findings highlight the incremental costs and healthcare burden of patients with chronic HCV infection associated with hospitalization.